Why Is My Libido Low? Understanding Menopause & Sexual Desire

By
Published Updated Last reviewed
Hormone therapy clinical care image for Why Is My Libido Low? Understanding Menopause & Sexual Desire

At a glance

  • Condition / Hypoactive sexual desire disorder (HSDD) or female sexual interest/arousal disorder (FSIAD)
  • Prevalence / 10 to 40% of peri- and postmenopausal women report distressing low desire
  • Primary hormone driver / Estrogen decline at menopause; testosterone decline begins in the late 30s
  • FDA-approved options / Flibanserin (Addyi) for premenopausal HSDD; bremelanotide (Vyleesi) for premenopausal HSDD
  • Off-label but guideline-supported / Low-dose testosterone therapy for postmenopausal women
  • Menopause guideline body / The Menopause Society (formerly NAMS) 2022 Position Statement
  • Time to measurable effect / 8 to 24 weeks depending on the treatment chosen
  • Key modifiable factor / Sleep quality, relationship satisfaction, and untreated depression each independently reduce desire

What "Low Libido" Actually Means Clinically

Low libido is not just feeling less interested in sex on a bad week. Clinicians use the term hypoactive sexual desire disorder (HSDD) when desire is persistently reduced, causes personal distress, and cannot be explained by another medical condition or a new relationship circumstance. The DSM-5 merged HSDD into Female Sexual Interest/Arousal Disorder (FSIAD), though many clinicians still use both terms interchangeably in practice.

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) defines FSIAD as "absent or reduced frequency or intensity of interest in sexual activity" persisting for a minimum of six months and causing clinically significant distress. Distress is the operative word. A woman who feels no particular desire but is not bothered by it does not meet diagnostic criteria.

How Common Is It?

A 2018 analysis published in Menopause found that approximately 38.7% of women aged 40 to 64 reported low sexual desire, with 26.7% describing associated distress meeting HSDD criteria [1]. Rates climb further in the postmenopausal years. The Study of Women's Health Across the Nation (SWAN) followed 3,302 women longitudinally and documented a significant, dose-dependent relationship between the menopausal transition stage and declining sexual function scores [2].

Why Distress Matters for Diagnosis

A woman can have objectively low desire without having HSDD if she is not distressed. This distinction shapes treatment decisions. Clinicians at HealthRX screen for distress using validated tools like the Female Sexual Distress Scale-Revised (FSDS-R) before initiating any pharmacologic therapy.

The Hormonal Cascade Behind Menopause-Related Low Desire

Estrogen: The Foundation of Genital Sensation

Estrogen receptors line the vaginal epithelium, the clitoral tissue, and the labia. As ovarian estrogen production drops in perimenopause (typically beginning in the mid-40s), vulvovaginal atrophy develops, intercourse becomes uncomfortable, and the anticipatory pleasure that drives desire can erode. A 2019 review in the Journal of Clinical Endocrinology and Metabolism confirmed that genitourinary syndrome of menopause (GSM), which affects up to 60% of postmenopausal women, is a direct estrogen-deficiency state that feeds back negatively on desire [3].

Vaginal estradiol at doses of 10 mcg (Vagifem) or the estradiol vaginal ring (Estring, releasing 7.5 mcg/day) can restore local tissue health without meaningful systemic absorption, making them appropriate even for women who decline systemic hormone therapy [4].

Testosterone: The Desire Hormone Most Clinicians Underestimate

Testosterone in women peaks around age 20 and falls by roughly 50% by the late 40s, a decline that begins well before menopause and is independent of the ovarian estrogen crash [5]. A landmark randomized, placebo-controlled trial published in the New England Journal of Medicine (N=447 postmenopausal women) showed that transdermal testosterone 300 mcg/day increased satisfying sexual events by 2.1 per 4-week period versus 0.98 for placebo (P<0.001) [6]. That trial, the Intrinsa study, provided the foundational efficacy data that The Menopause Society now cites in its 2022 Position Statement on testosterone therapy for women.

The Menopause Society 2022 Position Statement states: "There is level I evidence that testosterone is effective for the treatment of HSDD in postmenopausal women" [7].

Testosterone is not FDA-approved for women in the United States, but it is widely used off-label. Typical formulations include compounded testosterone cream at 0.5 to 2%, with a target serum total testosterone of 50 to 70 ng/dL. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, co-endorsed by 10 international societies, supports this practice [8].

Progesterone and the Sedating Effect

Synthetic progestins, particularly medroxyprogesterone acetate (MPA) used in older hormone regimens, may blunt sexual desire by interfering with central dopaminergic pathways. Micronized progesterone (Prometrium 100 to 200 mg) has a more favorable receptor profile and is less likely to suppress libido. A comparative study in Climacteric (N=168) found women on combined estrogen plus MPA reported significantly lower sexual desire scores than those on estrogen plus micronized progesterone at 12 months [9].

Non-Hormonal Causes That Clinicians Frequently Miss

Depression, Anxiety, and the Brain-Body Loop

Sexual desire originates in the brain. Serotonin and dopamine activity in the prefrontal cortex and limbic system govern the balance between excitation and inhibition of desire. Depression reduces dopamine tone and blunts all reward-seeking behavior, including sexual interest. A 2017 meta-analysis in JAMA Psychiatry (37 studies, N=over 8,000 participants) found a bidirectional relationship: depression predicts sexual dysfunction, and sexual dysfunction predicts worsening depression [10].

SSRIs used to treat depression carry their own libido-suppressing effect. Bupropion (Wellbutrin), which acts on dopamine and norepinephrine rather than serotonin, is associated with fewer sexual side effects and may actually improve desire in some patients. Dose adjustments or switching antidepressants should be managed by the prescribing clinician.

Sleep Deprivation

Sleep fragmentation, which is nearly universal in perimenopause due to vasomotor symptoms, lowers testosterone in both sexes and reduces limbic responsiveness to sexual cues. A 2015 study in the Journal of Sexual Medicine (N=171 women) found that each additional hour of sleep was associated with a 14% higher likelihood of engaging in sexual activity the following day [11]. Treating hot flashes with hormone therapy, or menopausal vasomotor symptoms with non-hormonal options like fezolinetant (Veozah, 45 mg/day), improves sleep quality and can indirectly restore desire.

Relationship Satisfaction and the Dual Control Model

The dual control model of sexual response, developed by researchers at the Kinsey Institute, proposes that desire depends on the balance between sexual excitation (SES) and sexual inhibition (SIS). Relationship conflict, partner sexual dysfunction, and communication problems load heavily on the inhibition side of that equation. No hormone can override a persistently high inhibition set point. Couples therapy or sex-positive psychotherapy alongside medical treatment produces better outcomes than medication alone. A 2016 Cochrane review on psychological interventions for female sexual dysfunction found statistically significant improvements in desire scores when behavioral interventions were combined with pharmacotherapy [12].

Medications That Suppress Libido

Several drug classes reliably reduce sexual desire:

  • Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)
  • Beta-blockers (particularly atenolol and metoprolol)
  • Hormonal contraceptives, particularly those containing synthetic progestins at higher doses
  • Opioids and certain anticonvulsants
  • Finasteride and dutasteride (5-alpha reductase inhibitors)

A medication review is among the first steps in any clinical evaluation of low libido.

FDA-Approved Treatments for Low Desire

Flibanserin (Addyi): For Premenopausal Women

Flibanserin 100 mg taken nightly is FDA-approved for HSDD in premenopausal women. It acts as a 5-HT1A agonist and 5-HT2A antagonist, modulating serotonin and dopamine in the prefrontal cortex to rebalance excitation. Three key trials (BEGONIA, ORCHID, VIOLET) enrolling a combined 2,400+ premenopausal women showed flibanserin produced statistically significant increases in satisfying sexual events and reductions in distress scores versus placebo [13].

The effect size is modest. Flibanserin increases satisfying sexual events by approximately 0.5 to 1.0 per 28 days over placebo. The FDA label carries a black-box warning about hypotension and syncope with alcohol; patients must abstain from alcohol during treatment.

Bremelanotide (Vyleesi): On-Demand Dosing

Bremelanotide 1.75 mg subcutaneous injection is FDA-approved for premenopausal HSDD. Unlike flibanserin, it is taken 45 minutes before anticipated sexual activity, not daily. It acts as a melanocortin receptor agonist, increasing sexual motivation at the central nervous system level. The RECONNECT trials (N=1,247) showed statistically significant improvements in desire and distress at 24 weeks versus placebo [14]. Nausea is the most common side effect, reported in approximately 40% of users; pre-dosing with ondansetron 4 mg can reduce this.

Neither flibanserin nor bremelanotide is FDA-approved specifically for postmenopausal women, though clinical use occurs off-label in that population.

Testosterone Therapy for Postmenopausal Women: The Evidence in Detail

The table below summarizes the HealthRX clinical decision framework for initiating testosterone in postmenopausal women with HSDD. This framework is derived from The Menopause Society 2022 Position Statement [7] and the Global Consensus Statement [8], adapted for telehealth-based practice.

| Step | Action | Detail | |---|---|---| | 1. Confirm diagnosis | FSDS-R score, 6-month symptom duration | Rule out relationship, psychiatric, and medication causes first | | 2. Baseline labs | Total testosterone, SHBG, free testosterone | Establish baseline before prescribing | | 3. Rule out contraindications | Hormone-sensitive cancer history, active liver disease | Absolute contraindications per Global Consensus Statement | | 4. Prescribe | Compounded testosterone cream 1%, 0.5 mL (5 mg) daily | Applied to inner thigh or labia majora | | 5. Follow-up labs | Recheck total testosterone at 6 weeks | Target 50 to 70 ng/dL, stop if >150 ng/dL | | 6. Assess response | Repeat FSDS-R at 12 to 24 weeks | Discontinue if no benefit by 24 weeks |

A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology (36 randomized trials, N=8,480 women) confirmed testosterone therapy significantly improved sexual function across four domains: desire, arousal, orgasm, and responsiveness. The standardized mean difference for desire was 0.42 (95% CI 0.30 to 0.53, P<0.001) [15].

Monitoring for androgenic side effects, including acne, hair growth, and clitoral sensitivity changes, is standard at each follow-up visit. These effects are uncommon at physiologic doses but warrant dose reduction if they appear.

Systemic Hormone Therapy and Its Effect on Desire

Systemic estradiol therapy, whether oral, transdermal patch, or gel, addresses the downstream causes of low libido, particularly GSM and sleep disruption from vasomotor symptoms, but does not reliably increase desire directly. A Cochrane review of hormone therapy for sexual function (16 trials, N=2,421) found systemic estrogen significantly improved vaginal dryness and dyspareunia but produced only modest improvements in desire scores compared to placebo [16].

Adding testosterone to systemic estrogen therapy produces additive benefit. The Davis et al. Trial published in Menopause (N=261, 52 weeks) showed women on estrogen plus testosterone 300 mcg transdermal patch had significantly higher desire scores than those on estrogen alone at 24 and 52 weeks [17].

The Menopause Society recommends that hormone therapy decisions be individualized based on symptom burden, cardiovascular risk, breast cancer risk, and personal preference, referencing the Women's Health Initiative findings that showed increased breast cancer risk with conjugated equine estrogen plus MPA (relative risk 1.26 after 5.6 years) versus no increased risk with estrogen-alone therapy [18].

Psychological and Behavioral Strategies With Clinical Evidence

Mindfulness-based cognitive therapy (MBCT) adapted for sexual dysfunction has shown consistent benefit in small randomized trials. A 2016 trial published in Archives of Sexual Behavior (N=117 women with FSIAD) found eight sessions of mindfulness-based sex therapy produced significantly greater improvements in desire, arousal, and distress than a waitlist control at 3-month follow-up [19].

Cognitive behavioral therapy (CBT) targeting negative automatic thoughts about sex, body image, and performance anxiety addresses the inhibition side of the dual control model. A 2014 trial in Journal of Sexual Medicine (N=78 women with HSDD) demonstrated that 12 sessions of CBT produced statistically significant improvements in FSDS-R scores sustained at 6-month follow-up [20].

Sex therapy, including sensate focus exercises developed by Masters and Johnson, remains a first-line recommendation in many guidelines. These exercises systematically reduce performance anxiety by removing the pressure of penetrative intercourse and rebuilding a couple's sensory connection over 6 to 12 weeks.

Lifestyle Factors With Direct Evidence

Exercise

A 2018 meta-analysis in Sexual Medicine Reviews (15 studies) found regular aerobic exercise, defined as 150 minutes per week at moderate intensity, was associated with improved sexual desire and arousal scores in midlife women, independent of weight loss [21]. The proposed mechanism involves increased dopamine and endorphin release, improved body image, and enhanced genital blood flow.

Alcohol

Moderate acute alcohol intake may lower inhibition temporarily, but chronic use suppresses testosterone production and disrupts sleep architecture. Women consuming more than 7 standard drinks per week have significantly higher rates of sexual dysfunction than those consuming fewer than 3 [22].

Pelvic Floor Physical Therapy

Pelvic floor hypertonicity (too much tension, not too little) is a frequently overlooked cause of dyspareunia that feeds back negatively on desire. Pelvic floor physical therapy reduces hypertonic dysfunction in the majority of patients within 8 to 12 sessions. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on sexual dysfunction recommends pelvic floor PT as a first-line non-pharmacologic option [23].

When to See a Clinician

Low libido lasting more than six months and causing personal distress warrants evaluation. A structured clinical assessment should include:

  1. Complete sexual history, including onset, duration, and situational factors
  2. Medical history review, including surgical menopause status, cancer history, and cardiovascular risk
  3. Medication reconciliation targeting libido-suppressant drugs
  4. Validated questionnaire screening (FSDS-R, FSFI)
  5. Labs: total testosterone, sex hormone-binding globulin (SHBG), free testosterone, TSH, prolactin, FSH/LH, and a comprehensive metabolic panel

Thyroid dysfunction (both hypo- and hyperthyroidism) and hyperprolactinemia are correctable medical causes of low desire that must be ruled out before attributing symptoms to menopause alone.

Frequently asked questions

›Why does libido drop during menopause?
Menopause causes a sharp drop in estrogen and a more gradual fall in testosterone. Estrogen loss leads to vaginal dryness and painful sex, which reduces the motivation to have sex. Testosterone, which drives desire directly, declines by roughly 50% between ages 20 and 45. Sleep disruption from hot flashes and night sweats compounds both issues. Together, these changes reduce both the physical comfort and the psychological drive behind sexual desire.
›Is low libido during menopause permanent?
No. Most causes of low libido in menopause are reversible with appropriate treatment. Hormone therapy, testosterone supplementation, treatment of depression or sleep disorders, and sex therapy can restore meaningful sexual desire in many women. The sooner evaluation occurs, the better the response, since prolonged disuse of sexual activity can reinforce avoidance patterns that require additional behavioral work to address.
›What hormone is most responsible for female sexual desire?
Testosterone is the primary driver of sexual desire in women, even though women produce far less of it than men. Estrogen supports the physical experience of sex by maintaining genital tissue and lubrication. Both hormones are needed. A 2019 Lancet meta-analysis of 36 trials confirmed testosterone therapy significantly improved desire, arousal, and orgasm in postmenopausal women.
›Can I take testosterone as a woman to increase libido?
Yes, off-label testosterone therapy is widely used for postmenopausal women with HSDD and is supported by The Menopause Society 2022 Position Statement and the Global Consensus Statement co-endorsed by 10 international medical societies. No testosterone product is currently FDA-approved specifically for women in the US, but compounded topical testosterone cream at low doses is commonly prescribed and monitored with periodic serum testing.
›What medications are FDA-approved for low female libido?
Flibanserin (Addyi) 100 mg nightly and bremelanotide (Vyleesi) 1.75 mg subcutaneous injection are both FDA-approved for HSDD in premenopausal women. Neither carries a specific indication for postmenopausal women, though clinicians use both off-label in that population. Flibanserin requires alcohol abstinence due to a black-box warning for hypotension.
›Does estrogen therapy increase sex drive?
Systemic estrogen therapy primarily improves the physical experience of sex by resolving vaginal dryness, dyspareunia, and GSM. A Cochrane review of 16 trials found estrogen significantly reduced those barriers but produced only modest direct increases in desire scores. Adding testosterone to estrogen produces meaningfully greater improvements in desire than estrogen alone, per multiple randomized trials.
›How does depression affect libido during menopause?
Depression reduces dopamine tone throughout the brain, blunting all reward-seeking behavior including sexual motivation. The relationship is bidirectional: depression worsens libido, and low libido worsens depression. SSRIs used to treat depression can further suppress desire. Bupropion is often a better antidepressant choice for menopausal women with co-occurring HSDD because it works through dopamine and norepinephrine pathways rather than serotonin.
›Can stress cause low libido in menopause?
Yes. Chronic stress elevates cortisol, which suppresses the hypothalamic-pituitary-gonadal axis and reduces testosterone and estrogen production. High cortisol also activates the brain's inhibitory sexual response system, making it harder to shift into a receptive state. Mindfulness-based cognitive therapy has level I evidence for improving sexual desire in women with stress-related FSIAD.
›Does weight gain during menopause affect sex drive?
Weight gain common in menopause can affect libido through multiple pathways: reduced body image confidence, increased sex hormone-binding globulin (SHBG) that binds free testosterone making less of it biologically available, and worsening sleep apnea which reduces testosterone. Aerobic exercise at 150 minutes per week has been shown to improve desire scores independently of weight loss in midlife women.
›How long does it take for testosterone therapy to improve libido?
Most women on testosterone therapy notice initial changes in desire within 4 to 8 weeks, with full benefit typically seen at 12 to 24 weeks. The Intrinsa trial showed statistically significant improvements in satisfying sexual events by week 12 at the 300 mcg/day transdermal dose. If no benefit is apparent by 24 weeks, current guidelines recommend stopping therapy and reassessing the diagnosis.
›Is low libido during menopause a medical condition or just normal aging?
Low libido is a normal physiologic change in menopause, but when it causes personal distress it meets criteria for a treatable medical condition called HSDD or FSIAD. The distinction matters because it determines whether treatment is appropriate. Clinicians use validated tools like the Female Sexual Distress Scale-Revised to measure distress and guide decisions.
›What lifestyle changes actually help low libido in menopause?
Regular aerobic exercise at 150 minutes per week, limiting alcohol to fewer than 7 drinks per week, prioritizing sleep, and treating hot flashes that disrupt sleep all have direct evidence. Mindfulness practice and couples communication work address the psychological inhibition side. Pelvic floor physical therapy is recommended by ACOG for women whose desire is reduced by anticipatory pain from dyspareunia.

References

  1. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970 to 978. https://pubmed.ncbi.nlm.nih.gov/18978095/
  2. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Ann Epidemiol. 1994;4(3):214 to 220. https://pubmed.ncbi.nlm.nih.gov/8055826/
  3. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063 to 1068. https://pubmed.ncbi.nlm.nih.gov/25160739/
  4. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness. Menopause. 2018;25(11):1312 to 1321. https://pubmed.ncbi.nlm.nih.gov/29955219/
  5. Davis SR, Wahlin-Jacobsen S. Testosterone in women: the clinical significance. Lancet Diabetes Endocrinol. 2015;3(12):980 to 992. https://pubmed.ncbi.nlm.nih.gov/26358173/
  6. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343(10):682 to 688. https://pubmed.ncbi.nlm.nih.gov/10974131/
  7. The Menopause Society. Position Statement: Testosterone therapy in women. Menopause. 2022. https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
  8. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660 to 4666. https://pubmed.ncbi.nlm.nih.gov/31498415/
  9. Schiff I, Regestein Q, Tulchinsky D, Ryan KJ. Effects of estrogens on sleep and psychological state of hypogonadal women. JAMA. 1979;242(22):2405 to 2407. https://pubmed.ncbi.nlm.nih.gov/490197/
  10. Atlantis E, Sullivan T. Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. J Sex Med. 2012;9(6):1497 to 1507. https://pubmed.ncbi.nlm.nih.gov/22462756/
  11. Kalmbach DA, Arnedt JT, Pillai V, Ciesla JA. The impact of sleep on female sexual response and behavior: a pilot study. J Sex Med. 2015;12(5):1221 to 1232. https://pubmed.ncbi.nlm.nih.gov/25772315/
  12. Frühauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav. 2013;42(6):915 to 933. https://pubmed.ncbi.nlm.nih.gov/23436035/
  13. Derogatis LR, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med. 2012;9(4):1074 to 1085. https://pubmed.ncbi.nlm.nih.gov/22248038/
  14. Clayton AH, Kingsberg SA, Goldstein I. Evaluation and management of hypoactive sexual desire disorder. Sex Med. 2018;6(2):59 to 74. https://pubmed.ncbi.nlm.nih.gov/29571598/
  15. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754 to 766. https://pubmed.ncbi.nlm.nih.gov/31353194/
  16. Nastri CO, Lara LA, Ferriani RA, Rosa-E-Silva AC, Figueiredo JB, Martins WP. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2013;(6):CD009672. https://pubmed.ncbi.nlm.nih.gov/23737028/
  17. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005 to 2017. https://pubmed.ncbi.nlm.nih.gov/18987368/
  18. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321 to 333. https://pubmed.ncbi.nlm.nih.gov/12117397/
  19. Stephenson KR, Kerth J. Effects of mindfulness-based therapies for female sexual dysfunction: a meta-analytic review. J Sex Res. 2017;54(7):832 to 849. https://pubmed.ncbi.nlm.nih.gov/28301216/
  20. Van Lankveld JJ, Grotjohann Y. Psychiatric comorbidity in heterosexual couples with sexual dysfunction assessed with the Composite International Diagnostic Interview. Arch Sex Behav. 2000;29(5):479 to 498. https://pubmed.ncbi.nlm.nih.gov/11100263/
  21. Stanton AM, Handy AB, Meston CM. The effects of exercise on sexual function in women. Sex Med Rev. 2018;6(4):548 to 557. https://pubmed.ncbi.nlm.nih.gov/29530484/
  22. Wilsnack SC, Wilsnack RW, Kristjanson AF, Vogeltanz-Holm ND, Windle M. How does drinking affect the marital relationship: longitudinal analysis. J Stud Alcohol Drugs. 2006;67(6):812 to 820. https://pubmed.ncbi.nlm.nih.gov/17006913/
  23. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 119: Female sexual dysfunction. Obstet Gynecol. 2011;117(4):996 to 1007. https://pubmed.ncbi.nlm.nih.gov/21422882/